Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on decoding biology through the integration of technological innovations in various fields such as biology, chemistry, automation, data science, and engineering, ultimately aiming to industrialize drug discovery. The company reported an income before tax of -$464,788,000.00 showcasing its pre-tax profitability. Its gross profit stands at $13,601,000.00 highlighting the company's profitability from core operations. However, the company incurred an income tax expense of -$1,127,000.00 indicating its tax obligations. Additionally, Recursion Pharmaceuticals reported selling, general, and administrative expenses of $178,184,000.00 which indicate operational overhead costs. The company also incurred an interest expense of $1,572,000.00 reflecting its debt servicing obligations. In terms of drug development, Recursion is advancing several candidates including REC-994, currently in Phase IIa clinical trials for treating cerebral cavernous malformation; REC-2282 for neurofibromatosis type 2; REC-4881 for familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trials for GM2 gangliosidosis. Its pipeline further includes various preclinical stage products targeting different conditions. The company has collaborative agreements with entities such as Bayer AG and the University of Utah Research Foundation, contributing to its research and development initiatives. Recursion Pharmaceuticals was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Investors may find the stock is affordable at $5.59 making it suitable for budget-conscious individuals. The stock enjoys a high average trading volume of 26,036,851.00 indicating strong liquidity within the market. With a mid-range market capitalization of $2,234,082,630.00 the company is viewed as a steady performer. It holds a significant position in the Biotechnology industry, contributing meaningfully to the overall market landscape. Furthermore, Recursion Pharmaceuticals belongs to the Healthcare sector, driving innovation and growth within the field. Overall, the company presents an intriguing opportunity for those looking to invest in a biotechnology firm actively engaged in addressing diverse medical needs through its innovative drug development efforts.